

## **Suzanne Hagan PhD**

Dept of Vision Sciences, Glasgow Caledonian University (GCU), Scotland, UK

[suzanne.hagan@gcu.ac.uk](mailto:suzanne.hagan@gcu.ac.uk)

### **Employment**

**Lecturer**, Department of Vision Science, GCU, Scotland, UK. (Jan 2010-present).

**Post-doctoral Research Scientist**, Department of Biological Sciences, GCU. (Aug 2007-Dec 2009).

**Post-Doctoral Research Scientist**, Beatson Institute for Cancer Research, Glasgow, UK. (Aug 2002-July 2007).

### **Academic Qualifications**

Currently studying for PGC Learning and Teaching in Higher Education, GCU (2010-2011).

**PhD**, University of Liverpool (2002). Unit of Ophthalmology, Dept. of Medicine.

Thesis Title “**The Glycoprotein SPARC (Secreted Protein, Acidic and Rich in Cysteine) in Proliferative Retinal Disease**”.

**BSc (Hons)** 2:1 in Biochemistry, University of Liverpool.

### **Professional Memberships (past and present)**

Reviewer for British Contact Lens and Anterior Eye journal.

Member of Euromene (European ME network), a collaboration of 12 EU countries investigating pathogenesis of CFS/ME.

Member of The ME Observatory, a UK-based programme of research into CFS/ME).

Member of IACFS (International Association for CFS/ME)

Invited advisor to The Scottish Public Health Network (ScotPHN) – A Needs assessment of NHS services for people with CFS/ME.

### **List of Publications**

1. Groom HCT, Boucherit VC, Makinson K, Randal E, Baptista S, **Hagan S**, Gow JW, Mattes F, Breuer J, Kerr JR, Stoye JP, Bishop KN. (2010) Absence of

xenotropic murine leukaemia virus-related virus in UK patients with chronic fatigue syndrome. *Retrovirology*. **15(7)**:10.

2. Gow JW, **Hagan S**, Herzyk P, Cannon C, Behan PO, Chaudhuri A. (2009) A Gene Signature for Post-Infectious Chronic Fatigue Syndrome. *BMC Medical Genomics*. **2(1)**:38.
3. Al-Mulla F, **Hagan S**, Al-Ali W, Jacob SP, Behbehani AI, Bitar MS, Dallo A, Kolch W. (2008) Raf Kinase inhibitor protein: mechanism of loss of expression and association with genomic instability. *J. Clin. Path.* **61(4)**:524-29.
4. Patek CE, Arends MJ, Wallace WAH, Luo F, **Hagan S**, Brownstein DG, Rose L, Devenney PS, Walker M, Plowman SJ, Berry RL, Kolch W, Sansom OJ, Harrison DJ, Hooper ML. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. (2008) *Exp. Cell Res.* **314**:1105-14.
5. Dhillon AS, **Hagan S**, Rath O, Kolch W. (2007) MAP kinase signalling pathways in cancer. *Oncogene* **26**:3279-90.
6. Al-Mulla F, **Hagan S (joint 1<sup>st</sup> author)**, Behbehani AI, Bitar MS, George SS, Going JJ, García JJ, Scott L, Fyfe N, Murray GI, Kolch W. (2006) Raf kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. *J. Clin. Oncol.* **24**:5672-79.
7. **Hagan S**, Garcia R, Dhillon A, Kolch W. (2005) Raf kinase inhibitor protein regulation of Raf and MAPK signaling. *Methods Enzymol.* **407**:248-59.
8. **Hagan S**, Al-Mulla F, Mallon E, Oien K, Ferrier R, Gusterson B, García JJ, Kolch W. (2005) Reduction of Raf-1 kinase inhibitor protein expression correlates with breast cancer metastasis. *Clin. Can. Res.* **11**:7392-97.
9. Schuierer MM, Bataille F, **Hagan S**, Kolch W, Bosserhoff AK (2004) Reduction in Raf kinase inhibitor protein expression is associated with increased Ras-extracellular signal-regulated kinase signaling in melanoma cell lines. *Cancer Res.* **64**:5186-92.
10. **Hagan S**, Hiscott P, Sheridan CM, Wong D, Grierson I, McGalliard J. (2003) Effects of the matricellular protein SPARC on human retinal pigment epithelial cell behavior. *Mol. Vis.* **9**:87-92.
11. Sheridan CM, Magee RM, Hiscott PS, **Hagan S**, Wong DH, McGalliard JN, Grierson I. (2002) The role of matricellular proteins thrombospondin-1 and osteonectin during RPE cell migration in proliferative vitreoretinopathy. *Curr. Eye Res.* **25**:279-85.
12. Hiscott P, **Hagan S**, Heathcote L, Sheridan CM, Groenewald CP, Grierson I, Wong D, Paraoan L. (2002) Pathobiology of epiretinal and subretinal membranes:

possible roles for the matricellular proteins thrombospondin 1 and osteonectin (SPARC). *Eye* **16**:393-403.

13. Scholes AG, Liloglou T, Maloney P, **Hagan S**, Nunn J, Hiscott P, Damato BE, Grierson I, Field JK. (2001) Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. *Invest. Oph. Vis. Sci.* **42**:2472-77.
14. Scholes AG, **Hagan S**, Hiscott P, Damato BE, Grierson I. (2001) Overexpression of epidermal growth factor receptor restricted to macrophages in uveal melanoma. *Arch. Ophthalmol.* **119**:373-77.
15. Carron JA, Hiscott P, **Hagan S**, Sheridan CM, Magee R, Gallagher JA. (2000) Cultured human retinal pigment epithelial cells differentially express thrombospondin-1, -2, -3, and -4. *Int. J. Biochem. Cell Biol.* **32**:1137-42.
16. Grierson I, Heathcote L, Hiscott P, Hogg P, Briggs M, **Hagan S**. (2000) Hepatocyte growth factor/scatter factor in the eye. *Prog. Ret. Eye Res.* **19**:779-802.
17. Magee RM, **Hagan S**, Hiscott PS, Sheridan CM, Carron JA, McGalliard J, Grierson I. (2000) Synthesis of osteonectin by human retinal pigment epithelial cells is modulated by cell density. *Invest. Oph. Vis. Sci.* **41**:2707-11.